Lynx1 Capital Management LP Stoke Therapeutics, Inc. Transaction History
Lynx1 Capital Management LP
- $279 Million
- Q3 2024
A detailed history of Lynx1 Capital Management LP transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Lynx1 Capital Management LP holds 5,187,191 shares of STOK stock, worth $72.1 Million. This represents 22.82% of its overall portfolio holdings.
Number of Shares
5,187,191Holding current value
$72.1 Million% of portfolio
22.82%Shares
5 transactions
Others Institutions Holding STOK
# of Institutions
123Shares Held
57.3MCall Options Held
9.3KPut Options Held
35.2K-
Skorpios Trust8.91MShares$124 Million99.85% of portfolio
-
Black Rock Inc. New York, NY5.41MShares$75.2 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.71MShares$65.5 Million3.79% of portfolio
-
Rtw Investments, LP New York, NY4.65MShares$64.7 Million0.91% of portfolio
-
Baker Bros. Advisors LP New York, NY4.37MShares$60.7 Million0.57% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $548M
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...